A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

PHASE4WithdrawnINTERVENTIONAL

Timeline

Start Date

June 17, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Bladder CancerTa/T1CIS

Interventions

DRUG

nadofaragene firadenovec

The investigational medicinal product dose, concentration, and assessments are aligned with nadofaragene firadenovec US prescribing information.

Trial Locations (2)

Ferring Investigational Site, Atlanta

Ferring Investigational Site, Little Rock